Abstract:Many bacteria act pathogenic by the release of AB-type protein toxins that efficiently enter human or animal cells and act as enzymes in their cytosol. This leads to disturbed cell functions and the clinical symptoms characteristic for the individual toxin. Therefore, molecules that directly target and neutralize these toxins provide promising novel therapeutic options. Here, we found that the FDA-approved drug disulfiram (DSF), used for decades to treat alcohol abuse, protects cells from intoxication with diphtheria toxin (DT) from Corynebacterium diphtheria, the causative agent of diphtheria, lethal toxin (LT) from Bacillus anthracis, which contributes to anthrax, and C2 enterotoxin from Clostridium botulinum when applied in concentrations lower than those found in plasma of patients receiving standard DSF treatment for alcoholism (up to 20 µM). Moreover, this inhibitory effect is increased by copper, a known enhancer of DSF activity. LT and C2 are binary toxins, consisting of two non-linked proteins, an enzyme (A) and a separate binding/transport (B) subunit. To act cytotoxic, their proteolytically activated B subunits PA63 and C2IIa, respectively, form barrel-shaped heptamers that bind to their cellular receptors and form complexes with their respective A subunits LF and C2I. The toxin complexes are internalized via receptor-mediated endocytosis and in acidified endosomes, PA63 and C2IIa form pores in endosomal membranes, which facilitate translocation of LF and C2I into the cytosol, where they act cytotoxic. In DT, A and B subunits are located within one protein, but DT also forms pores in endosomes that facilitate translocation of the A subunit. If cell binding, membrane translocation, or substrate modification is inhibited, cells are protected from intoxication. Our results implicate that DSF neither affects cellular binding nor the catalytic activity of the investigated toxins to a relevant extend, but interferes with the toxin pore-mediated translocation of the A subunits of DT, LT and C2 toxin, as demonstrated by membrane-translocation assays and toxin pore conductivity experiments in the presence or absence of DSF. Since toxin translocation across intracellular membranes represents a central step during cellular uptake of many bacterial toxins, DSF might neutralize a broad spectrum of medically relevant toxins.

FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation

Identification of pyroptosis inhibitors that target a reactive cysteine in gasdermin D

Disulfiram Alleviates Acute Lung Injury and Related Intestinal Mucosal Barrier Impairment by Targeting GSDMD-dependent Pyroptosis.

FDA-approved disulfiram inhibits the NLRP3 inflammasome by regulating NLRP3 palmitoylation

Disulfiram Reduces Atherosclerosis and Enhances Efferocytosis, Autophagy, and Atheroprotective Gut Microbiota in Hyperlipidemic Mice

Disulfiram alleviates airway remodeling in ozone-induced chronic obstructive pulmonary disease mouse models via inhibiting Gasdermin D-mediated pyroptosis

A bacterial phospholipid phosphatase inhibits host pyroptosis by hijacking ubiquitin

Disulfiram attenuates hypoxia-induced pulmonary hypertension by inhibiting GSDMD cleavage and pyroptosis in HPASMCs

Inhibition of gasdermin D palmitoylation by disulfiram is crucial for the treatment of myocardial infarction

Treatment of Severe Acute Pancreatitis and Related Lung Injury by Targeting Gasdermin D-Mediated Pyroptosis

Disulfiram inhibits inflammation and fibrosis in a rat unilateral ureteral obstruction model by inhibiting gasdermin D cleavage and pyroptosis

Disulfiram ameliorates ischemia/reperfusion-induced acute kidney injury by suppressing the caspase-11-GSDMD pathway

Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis

Application of Disulfiram and its Metabolites in Treatment of Inflammatory Disorders

Disulfiram Improves Fat Graft Retention by Modulating Macrophage Polarization Via Inhibition of NLRP3 Inflammasome-Mediated Pyroptosis

Disulfiram, an Aldehyde Dehydrogenase Inhibitor, Works As a Potent Drug Against Sepsis and Cancer Via NETosis, Pyroptosis, Apoptosis, Ferroptosis, and Cuproptosis

Pyroptosis-mediator GSDMD Promotes Parkinson’s Disease Pathology Via Microglial Activation and Dopaminergic Neuronal Death

Pyroptosis inhibiting nanobodies block Gasdermin D pore formation

Disulfiram Protects Against Abdominal Aortic Aneurysm by Ameliorating Vascular Smooth Muscle Cells Pyroptosis.

Repurposing FDA-approved disulfiram for targeted inhibition of diphtheria toxin and the binary protein toxins of Clostridium botulinum and Bacillus anthracis